{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.7","upperLimit":"51.3","value":"20.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral everolimus once daily and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"All Patients (Everolimus and Lenalidomide)"}],"paramType":"MEDIAN","populationDescription":"Fifty-five patients began study treatment and were eligible for response evaluation were pooled and included in this analysis.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Overall Survival for All Eligible Patients","type":"SECONDARY","unitOfMeasure":"months"}